|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
1
|
|
pubmed:dateCreated |
2011-7-4
|
|
pubmed:abstractText |
A subgroup of patients with chronic spontaneous urticaria (CU) exhibits IgE antibodies directed against autoantigens, such as thyroperoxidase (TPO). We conducted this study to investigate whether such patients with CU with IgE against TPO benefit from treatment with omalizumab, a humanized anti-IgE mAb licensed for the treatment of severe persistent allergic (IgE-mediated) asthma.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
AIM
|
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Anti-Allergic Agents,
http://linkedlifedata.com/resource/pubmed/chemical/Antibodies, Anti-Idiotypic,
http://linkedlifedata.com/resource/pubmed/chemical/Antibodies, Monoclonal,
http://linkedlifedata.com/resource/pubmed/chemical/Antibodies, Monoclonal, Humanized,
http://linkedlifedata.com/resource/pubmed/chemical/Autoantibodies,
http://linkedlifedata.com/resource/pubmed/chemical/Autoantigens,
http://linkedlifedata.com/resource/pubmed/chemical/Immunoglobulin E,
http://linkedlifedata.com/resource/pubmed/chemical/omalizumab
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jul
|
|
pubmed:issn |
1097-6825
|
|
pubmed:author |
pubmed-author:AltrichterSabineS,
pubmed-author:BieberThomasT,
pubmed-author:BiedermannTiloT,
pubmed-author:BräutigamMatthiasM,
pubmed-author:BrehlerRandolfR,
pubmed-author:GrabbeJürgenJ,
pubmed-author:HunzelmannNicolasN,
pubmed-author:JakobThiloT,
pubmed-author:JungAndreasA,
pubmed-author:Kleine-TebbeJörgJ,
pubmed-author:MahlerVeraV,
pubmed-author:MaurerMarcusM,
pubmed-author:MempelMartinM,
pubmed-author:MeurerMichaelM,
pubmed-author:ReichKristianK,
pubmed-author:RuëffFranziskaF,
pubmed-author:SchäkelKnutK,
pubmed-author:SenguptaKaushikK,
pubmed-author:SeyfriedStefanS,
pubmed-author:SiederChristianC,
pubmed-author:SimonJan CJC,
pubmed-author:StaubachPetraP,
pubmed-author:WediBettinaB,
pubmed-author:ZuberbierTorstenT
|
|
pubmed:copyrightInfo |
Copyright © 2011 American Academy of Allergy, Asthma & Immunology. Published by Mosby, Inc. All rights reserved.
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
128
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
202-209.e5
|
|
pubmed:dateRevised |
2011-11-17
|
|
pubmed:meshHeading |
pubmed-meshheading:21636116-Adolescent,
pubmed-meshheading:21636116-Adult,
pubmed-meshheading:21636116-Aged,
pubmed-meshheading:21636116-Anti-Allergic Agents,
pubmed-meshheading:21636116-Antibodies, Anti-Idiotypic,
pubmed-meshheading:21636116-Antibodies, Monoclonal,
pubmed-meshheading:21636116-Antibodies, Monoclonal, Humanized,
pubmed-meshheading:21636116-Autoantibodies,
pubmed-meshheading:21636116-Autoantigens,
pubmed-meshheading:21636116-Female,
pubmed-meshheading:21636116-Humans,
pubmed-meshheading:21636116-Immunoglobulin E,
pubmed-meshheading:21636116-Male,
pubmed-meshheading:21636116-Middle Aged,
pubmed-meshheading:21636116-Urticaria,
pubmed-meshheading:21636116-Young Adult
|
|
pubmed:year |
2011
|
|
pubmed:articleTitle |
Efficacy and safety of omalizumab in patients with chronic urticaria who exhibit IgE against thyroperoxidase.
|
|
pubmed:affiliation |
Charité-Universitätsmedizin Berlin, Allergie-Centrum-Charité, Klinik für Dermatologie, Venerologie und Allergologie, Berlin, Germany. marcus.maurer@charite.de
|
|
pubmed:publicationType |
Journal Article,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't,
Multicenter Study
|
